Neuroleptic and anticholinergic drug use in Chinese patients with schizophrenia resident in a state psychiatric hospital in Singapore

Citation
Sa. Chong et al., Neuroleptic and anticholinergic drug use in Chinese patients with schizophrenia resident in a state psychiatric hospital in Singapore, AUST NZ J P, 34(6), 2000, pp. 988-991
Citations number
21
Categorie Soggetti
Psychiatry,"Clinical Psycology & Psychiatry
Journal title
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY
ISSN journal
00048674 → ACNP
Volume
34
Issue
6
Year of publication
2000
Pages
988 - 991
Database
ISI
SICI code
0004-8674(200012)34:6<988:NAADUI>2.0.ZU;2-2
Abstract
Objective: The objective of this study was to survey the prescribing patter n in Chinese patients with chronic schizophrenia in a state mental hospital in Singapore, and to compare our findings with those of surveys of Chinese patients in other countries. Method: We surveyed the use of neuroleptic and anticholinergic agents among Chinese patients with chronic schizophrenia (n = 534) in a state mental ho spital in Singapore. Results: Fifty-nine per cent of the patients received two or more neurolept ics (median daily dose of 400 mg chlorpromazine equivalents, range 50-2875 mg). There were no differences in gender distribution between those prescri bed multiple neuroleptics as against an older group of those receiving none or only one neuroleptic medication. Sixty-six per cent of the patients wer e receiving depot neuroleptics, with more than half of these subjects also receiving additional oral neuroleptics, Patients who were prescribed multip le neuroleptics received significantly higher total doses than those receiv ing just one neuroleptic. Only 1% of patients were prescribed an atypical n euroleptic. Sixty-five per cent of patients were prescribed an anticholiner gic agent. Those prescribed anticholinergic agents were younger, in receipt of higher doses of neuroleptic medications and had lower Simpson-Angus sco res for extrapyramidal side-effects. Conclusions: The pervasive use of multiple typical neuroleptics, marked und erutilisation of atypical neuroleptics, and the lack of anticholinergic med ication in patients who might benefit from such treatment are issues of sub stantial concern, warranting action in both psychiatry practice and mental health policy.